» Articles » PMID: 23994159

Insulin Suppresses Ischemic Preconditioning-mediated Cardioprotection Through Akt-dependent Mechanisms

Overview
Date 2013 Sep 3
PMID 23994159
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

It is believed that the diabetic myocardium is refractory to cardioprotection by ischemic preconditioning (IPC) mainly because of impaired insulin signaling to phosphatidylinositol 3-kinase (PI3K) and protein kinase B (PKB or Akt). However, human as well as animal studies have clearly showed that the hearts of type 2 diabetic humans and animals may exhibit increased signaling through PI3K-Akt but yet are resistant to cardioprotection by IPC or ischemic post-conditioning. Therefore, this study was designed to determine whether activation of insulin signaling prior to IPC is detrimental for cardioprotection and to assess the role of insulin receptors (IRs) and Akt in mediating this effect. Wild-type (WT) hearts, hearts lacking IRs or hearts expressing an active form of Akt (myrAkt1) were perfused ex vivo using a Langendorff preparation and were subjected to IPC (3cycles of 5min ischemia followed by 5min reflow before 30min no flow ischemia and then by 45min reperfusion) in the presence or absence of 1nmol/L insulin. Interestingly, whereas insulin was protective against I/R (30min no flow ischemia and 45min reperfusion), it completely abolished cardioprotection by IPC in WT hearts but not in mice lacking insulin receptors (IRs) in cardiomyocytes (CIRKO) or in all cardiac cells (TIRKO). The suppression of IPC-mediated cardioprotection was mediated through downstream signaling to Akt and Gsk3β. In addition, transgenic induction of Akt in the heart was sufficient to abrogate IPC even when insulin was absent, further confirming the involvement of Akt in insulin's suppression of cardioprotection by IPC. These data provide evidence that excessive insulin signaling to Akt is detrimental for cardioprotection by IPC and could explain the failure of the diabetic myocardium to precondition.

Citing Articles

Association of different insulin resistance surrogates with all-cause and cardiovascular mortality among the population with cardiometabolic multimorbidity.

Zhang H, Tu Z, Liu S, Wang J, Shi J, Li X Cardiovasc Diabetol. 2025; 24(1):33.

PMID: 39844261 PMC: 11755928. DOI: 10.1186/s12933-025-02576-0.


Insulin-Heart Axis: Bridging Physiology to Insulin Resistance.

Caturano A, Galiero R, Vetrano E, Sardu C, Rinaldi L, Russo V Int J Mol Sci. 2024; 25(15).

PMID: 39125938 PMC: 11313400. DOI: 10.3390/ijms25158369.


Insulin and glycolysis dependency of cardioprotection by nicotinamide riboside.

Xiao Y, Wang Q, Zhang H, Nederlof R, Bakker D, Siadari B Basic Res Cardiol. 2024; 119(3):403-418.

PMID: 38528175 PMC: 11142987. DOI: 10.1007/s00395-024-01042-4.


Phenotype of higher post-load insulin response as a predictor of all-cause mortality and cardiovascular mortality in the Chinese non-diabetic population.

Shen X, He S, Wang J, Qian X, Wang H, Zhang B Diabetol Metab Syndr. 2022; 14(1):19.

PMID: 35090539 PMC: 8796343. DOI: 10.1186/s13098-022-00786-0.


mTOR Mediated Metabolic Rewiring and Ischemic Preconditioning, its Complicated.

Abel E Circ Res. 2021; 128(5):652-654.

PMID: 34219792 PMC: 8244748. DOI: 10.1161/circresaha.121.318874.


References
1.
. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

2.
Vogt A, Htun P, Kluge A, Zimmermann R, Schaper W . Insulin-like growth factor-II delays myocardial infarction in experimental coronary artery occlusion. Cardiovasc Res. 1997; 33(2):469-77. DOI: 10.1016/s0008-6363(96)00212-x. View

3.
Jonassen A, Sack M, Mjos O, Yellon D . Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res. 2001; 89(12):1191-8. DOI: 10.1161/hh2401.101385. View

4.
Lee T, Chou T . Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab. 2003; 88(2):531-7. DOI: 10.1210/jc.2002-020904. View

5.
Aguilar D, Solomon S, Kober L, Rouleau J, Skali H, McMurray J . Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation. 2004; 110(12):1572-8. DOI: 10.1161/01.CIR.0000142047.28024.F2. View